Central vein sign and iron rim in multiple sclerosis: ready for clinical use?

Paolo Preziosa, Maria A Rocca, Massimo Filippi

Journal: Current opinion in neurology 2021;34(4):505-513

PMID: 33928930

Abstract

PURPOSE OF REVIEW

To summarize recent evidence from the application of susceptibility-based MRI sequences to investigate the 'central vein sign' (CVS) and 'iron rim' as biomarkers to improve the diagnostic work-up of multiple sclerosis (MS) and predict disease severity.

RECENT FINDINGS

The CVS is a specific biomarker for MS being detectable from the earliest phase of the disease. A threshold of 40% of lesions with the CVS can be optimal to distinguish MS from non-MS patients. Iron rim lesions, reflecting chronic active lesions, develop in relapsing-remitting MS patients and persist in progressive MS. They increase in size in the first few years after their formation and then stabilize. Iron rim lesions can distinguish MS from non-MS patients but not the different MS phenotypes. The presence of at least four iron rim lesions is associated with an earlier clinical disability, higher prevalence of clinically progressive MS and more severe brain atrophy. Automated methods for CVS and iron rim lesion detection are under development to facilitate their quantification.

SUMMARY

The assessment of the CVS and iron rim lesions is feasible in the clinical scenario and provides MRI measures specific to MS pathological substrates, improving diagnosis and prognosis of these patients.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Address: Neuroimaging Research Unit, Division of Neuroscience.; Neurology Unit.; Vita-Salute San Raffaele University, Milan, Italy.; Neurorehabilitation Unit.; Neurophysiology Service, IRCCS San Raffaele Scientific Institute.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.